RayKnowChina Research Map
Shortlist0

ChongqingChongqing Medical University

First Affiliated Hospital of Chongqing Medical University

重庆医科大学附属第一医院

Listed for 21 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Chongqing Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
  3. Hepatocellular carcinoma肝细胞癌64 papers led1 open trial led
  4. Stomach cancer胃癌35 papers led
  5. Osteosarcoma骨肉瘤25 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤12 papers led1 open trial led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Ewing sarcoma尤文肉瘤2 papers led
  9. Multiple myeloma多发性骨髓瘤4 papers led
  10. Aplastic anaemia再生障碍性贫血1 paper led
  11. Beta thalassaemiaβ 地中海贫血1 paper led
  12. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病8 papers led
  13. IgG4-related diseaseIgG4相关性疾病2 papers led
  14. Myasthenia gravis重症肌无力10 papers led
  15. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症5 papers led
  18. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  19. Behçet disease白塞病28 papers led
  20. IgA nephropathyIgA 肾病1 paper led
  21. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 1120242025: 332025

6 hospitals in Chongqing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesInduction / concurrent chemotherapyRadiotherapy techniqueRecurrent / metastatic disease
Departments in papersMedical oncologyENT / head & neck surgeryRadiology / nuclear medicine
Papers it led8
  1. Maintenance treatment with oral anticancer agents after first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  2. TGF-β-induced acetylation of KLF5 drives TNFAIP2 transcription and EMT in nasopharyngeal carcinoma: Unveiling a novel regulatory mechanism.2025Experimental cell research
  3. Sesamin Exerts Anti-Tumor Activity in Nasopharyngeal Carcinoma Through Inducing Autophagy and Reactive Oxygen Species Production.2025Frontiers in bioscience (Landmark edition)
  4. Novel prediction model combining PET/CT metabolic parameters, inflammation markers, and TNM stage: prospects for personalizing prognosis in nasopharyngeal carcinoma.2024Annals of nuclear medicine
  5. Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma.2023Epigenomics
  6. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  7. The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  8. The prognostic role of prognostic nutritional index in nasopharyngeal carcinoma: A systematic review and meta-analysis.2021International journal of clinical oncology
More papers found outside PubMed (not counted)7
  1. Current Status of Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma2025Journal of Innovations in Medical Researcharticle
  2. Triple-modality nanotheranostics for nasopharyngeal carcinoma: porphyrin-driven photothermal-chemo-radiosensitization with MRI-guided precision2025Frontiers in Nanotechnologyarticle
  3. A Review of the Role of DWI in Radiation Therapy Planning and Treatment Response Assessment for NPC Management2023Current Research in Medical Sciencesarticle
  4. Clinical Researches of Magnetic Resonance Diffusion Weighted Imaging in Radiotherapy of Nasopharyngeal Carcinoma2023Journal of Clinical Medicine Researcharticle
  5. Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma2022Figsharedataset
  6. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncologyconference-abstract
  7. The microRNA-451a/chromosome segregation 1-like axis suppresses cell proliferation, migration, and invasion and induces apoptosis in nasopharyngeal carcinoma2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 2220242025: 002025

7 hospitals in Chongqing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyMolecular markers & genomics
Departments in papersGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led7
  1. Senolytic elimination of therapy-induced senescent cells by ABT-263 improves chemotherapeutic efficacy in esophageal squamous cell carcinoma.2026Biochemical pharmacology
  2. Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway.2024Cancer gene therapy
  3. SH2D4A inhibits esophageal squamous cell carcinoma progression through FAK/PI3K/AKT signaling pathway.2024Cellular signalling
  4. Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study.2023BMC surgeryFree full text
  5. Long noncoding RNA GK-IT1 promotes esophageal squamous cell carcinoma by regulating MAPK1 phosphorylation.2022Cancer medicineFree full text
  6. Untargeted metabolomics analysis of esophageal squamous cell cancer progression.2022Journal of translational medicineFree full text
  7. Survival differences between chemotherapy and chemoradiotherapy in metastatic esophageal cancer: a propensity score-matched study based on the SEER database.2021Annals of palliative medicine
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)12
  1. Combining the Albumin-to-fibrinogen ratio and pathologic factors predicts survival in surgically treated patients with esophageal squamous cell carcinoma2024ONCOLOGIEarticle
  2. PREDICTIVE VALUE OF RCCEP IN THE OUTCOME OF PATIENTS WITH ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA TREATED WITH CAMRELIZUMAB2024Journal of Pharmaceutical and Medical Researcharticle
  3. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figsharedataset
  8. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  9. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  10. Capsaicin inhibits migration and invasion via inhibiting epithelial-mesenchymal transition in esophageal squamous cell carcinoma by up-regulation of claudin-3 expression2022Journal of Functional Foodsarticle
  11. Knock-down of long non-coding RNA GK-IT1 inhibits proliferation and promotes apoptosis in esophageal carcinoma cells2021DOAJ (DOAJ: Directory of Open Access Journals)article
  12. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 64 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
64
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 8820222023: 131320232024: 191920242025: 13132025

5 hospitals in Chongqing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324473

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing

  2. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  3. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led64
  1. Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes.2026Academic radiology
  2. Self-confined catalytic DNA circuit for on-site nonenzymatic amplified microRNA imaging.2026Biosensors & bioelectronics
  3. MTFR2-Mediated Fission Drives Fatty Acid and Mitochondrial Co-Transfer from Hepatic Stellate Cells to Tumor Cells Fueling Oncogenesis.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Discovery of novel diagnostic biomarkers of hepatocellular carcinoma associated with immune infiltration.2025Annals of medicineFree full text
  5. Current status and perspectives of molecular mechanisms of gender difference in hepatocellular carcinoma: The tip of the iceberg?2025Bioscience trends
  6. Advancements in second-line treatment research for hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  7. Relationships Among Serological Indicators and In Vitro High-Throughput Drug Sensitivity Screening Results in Patients with Hepatocellular Carcinoma.2025Combinatorial chemistry & high throughput screening
  8. Efficacy of Tislelizumab plus Lenvatinib in hepatocellular carcinoma after curative hepatectomy: a real-world study.2025Frontiers in immunologyFree full text
  9. Liver resection versus radiofrequency ablation for solitary small hepatocellular carcinoma measuring ≤3 cm: a systematic review and meta-analysis.2025International journal of surgery (London, England)Free full text
  10. Impact of HIV Infection on Hepatocellular Carcinoma: A Long-Term Prognostic Analysis.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. M2 macrophages and tumor cells engage in a metabolic feedback loop to drive HCC progression.2025Scientific reportsFree full text
  12. Prognostic impact of tertiary lymphoid structures and cancer-associated fibroblasts in hepatocellular carcinoma with portal vein tumor thrombus.2025Scientific reportsFree full text
  13. Comparison of the efficacy of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma: A retrospective study.2025World journal of gastroenterologyFree full text
  14. Unraveling the therapeutic potential of Calculus Bovis in liver cancer: A novel step for targeted cancer treatment.2025World journal of gastroenterologyFree full text
  15. Laparoscopic liver resection utilizing the ventral avascular area of the inferior vena cava: A retrospective cohort study.2025World journal of gastroenterologyFree full text
  16. Surgical resection of late-stage hepatocellular carcinoma for patients having undergone combined HAIC, targeted and immunotherapy.2024Asian journal of surgery
  17. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.2024Bioscience trends
  18. Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  19. Inhibition of SIRT7 promotes STAT1 activation and STAT1-dependent signaling in hepatocellular carcinoma.2024Cellular signalling
  20. Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma.2024Combinatorial chemistry & high throughput screening
  21. Tumor suppressor CLCA1 inhibits angiogenesis via TGFB1/SMAD/VEGF cascade and sensitizes hepatocellular carcinoma cells to Sorafenib.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  22. CLCA1, a tumour suppressor in hepatocellular carcinoma.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  23. Preoperative CT features for characterization of vessels that encapsulate tumor clusters in hepatocellular carcinoma.2024European journal of radiology
  24. Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC.2024Frontiers in immunologyFree full text
  25. Prognostic value of tertiary lymphoid structures in hepatocellular carcinoma: a meta-analysis and systematic review.2024Frontiers in immunologyFree full text
  26. FBXO family genes promotes hepatocellular carcinoma via ubiquitination of p53.2024Journal of cancer research and clinical oncologyFree full text
  27. Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era.2024Journal of cancer research and clinical oncologyFree full text
  28. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.2024Journal of experimental & clinical cancer research : CRFree full text
  29. Effect of Preoperative Malnutrition Based on Albumin and BMI on Hepatocellular Carcinoma Surgery and Prediction of Risk Factors of Complications.2024Journal of gastrointestinal cancer
  30. Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer.2024Journal of nanobiotechnologyFree full text
  31. MTFR2-dependent mitochondrial fission promotes HCC progression.2024Journal of translational medicineFree full text
  32. Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.2024Lancet (London, England)
  33. Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial.2024Lancet (London, England)
  34. Deciphering the oncogenic potential of ADAM9 in hepatocellular carcinoma through bioinformatics and experimental approaches.2024Scientific reportsFree full text
  35. An ER-Horse Detonating Stress Cascade for Hepatocellular Carcinoma Nanotherapy.2023ACS nano
  36. miR-29a-5p regulates the malignant biological process of liver cancer cells through ARID2 regulation of EMT.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  37. Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis B.2023BMC gastroenterologyFree full text
  38. The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.2023BMC gastroenterologyFree full text
  39. Correlation of endoplasmic reticulum stress patterns with the immune microenvironment in hepatocellular carcinoma: a prognostic signature analysis.2023Frontiers in immunologyFree full text
  40. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  41. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing.2023Frontiers in immunologyFree full text
  42. LncRNA RPPH1 acts as a molecular sponge for miR-122 to regulate Wnt1/β-catenin signaling in hepatocellular carcinoma.2023International journal of medical sciencesFree full text
  43. Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  44. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.2023Journal of experimental & clinical cancer research : CRFree full text
  45. Frontline resection or liver transplantation in patients with single-nodule hepatocellular carcinoma.2023Liver international : official journal of the International Association for the Study of the Liver
  46. Elucidating Cuproptosis-Associated Genes in the Progression from Nash to HCC Using Bulk and Single-Cell RNA Sequencing Analyses and Experimental Validation.2023Medicina (Kaunas, Lithuania)Free full text
  47. An integrated analysis of Dynamin 1 Like: A new potential prognostic indicator in hepatocellular carcinoma.2023Molecular carcinogenesis
  48. Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway.2022Acta biochimica et biophysica SinicaFree full text
  49. A well-matched marriage of immunotherapy and radiofrequency ablation to reduce the relapse and progression of hepatocellular carcinoma.2022Bioscience trends
  50. Hepatic stellate cell exosome-derived circWDR25 promotes the progression of hepatocellular carcinoma via the miRNA-4474-3P-ALOX-15 and EMT axes.2022Bioscience trends
  51. Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening.2022Canadian journal of gastroenterology & hepatologyFree full text
  52. SLC17A2 Expression Correlates with Prognosis and Immune Infiltrates in Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  53. Genomic analysis quantifies pyroptosis in the immune microenvironment of HBV-related hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  54. Clinical features and outcomes of NAFLD-related hepatocellular carcinoma.2022The Lancet. Oncology
  55. Four-year experience with more than 1000 cases of total laparoscopic liver resection in a single center.2022World journal of gastroenterologyFree full text
  56. Circular RNA circSP3 promotes hepatocellular carcinoma growth by sponging microRNA-198 and upregulating cyclin-dependent kinase 4.2021AgingFree full text
  57. Successful conversion therapy through gastric transcatheter chemoembolization in advanced gastric cancer: A case report.2021Asian journal of surgery
  58. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.2021BMC cancerFree full text
  59. An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma.2021Bioscience reportsFree full text
  60. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.2021European journal of gastroenterology & hepatology
  61. Integrating transcriptomes and somatic mutations to identify RNA methylation regulators as a prognostic marker in hepatocellular carcinoma.2021Hepatobiliary & pancreatic diseases international : HBPD INT
  62. Identification of hub genes and candidate drugs in hepatocellular carcinoma by integrated bioinformatics analysis.2021MedicineFree full text
  63. IGF2BP1 Promotes the Liver Cancer Stem Cell Phenotype by Regulating MGAT5 mRNA Stability by m6A RNA Methylation.2021Stem cells and development
  64. Sintilimab plus IBI305 for hepatocellular carcinoma.2021The Lancet. Oncology
Chinese-language papers (not in the count)2
  1. [Correlation of peritumoral circWDR25 expression with the prognosis of patients with hepatocellular carcinoma after curative resection].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Down-regulating the expression of hypoxia-induced fatty acid binding protein 5 (FABP5) inhibits tumor angiogenesis in Huh7 cells].2021Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status8
  1. Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical StudyNot yet recruitingNCT07324473Lead sponsorPhase 2Start 2026-01
  2. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  3. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  4. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  5. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationActive, not recruitingNCT04639180Study sitePhase 3Start 2021-04
  6. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  7. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  8. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 35 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
35
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 8820212022: 3320222023: 8820232024: 111120242025: 552025

6 hospitals in Chongqing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  3. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicineMedical oncology
Papers it led35
  1. Burden, trends, driving factors, and predictions of gastric cancer: a cross-national comparative analysis of China, Japan, and South Korea.2025BMC cancerFree full text
  2. Laparoscopic gastrectomy versus open gastrectomy for gastric cancer in patients among octogenarians: a meta-analysis.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  3. Safety and efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy: a retrospective cohort study.2025Frontiers in immunologyFree full text
  4. Prognostic risk model of gastric adenocarcinoma based on exosome-related genes.2025MedicineFree full text
  5. Logical Analysis of Multiple miRNAs with Isothermal Molecular Classifiers Based on LATE-RCA.2025Nano letters
  6. Effects of HMGA2 on the biological characteristics and stemness acquisition of gastric cancer cells.2024Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  7. The effect of tumor budding on patients with gastric cancer.2024Asian journal of surgery
  8. A Retrospective Observational Study of Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer and Colorectal Cancer From a Single Center in the Recent 5 years.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  9. Precutting Endoscopic Band Ligation-Assisted Resection Is Safe and Effective for Treating Gastric Submucosal Tumors from the Muscularis Propria.2024Digestive diseases and sciences
  10. YTHDF1 Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer Cells via Upregulating TCF7 mRNA Translation.2024Frontiers in bioscience (Landmark edition)
  11. Safety and Feasibility of Electro-Vaporization of Ligamentum Teres Hepatis in Totally Laparoscopic Gastrectomy.2024Journal of laparoendoscopic & advanced surgical techniques. Part A
  12. FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner.2024Medical oncology (Northwood, London, England)
  13. Preoperative CT-based radiomics and deep learning model for predicting risk stratification of gastric gastrointestinal stromal tumors.2024Medical physics
  14. Predictive Value of Preoperative Peripheral Blood Inflammatory Markers for Surgical Site Infection in Laparoscopic Radical Gastrectomy for Gastric Cancer.2024Surgical infections
  15. Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States.2024The American journal of gastroenterologyFree full text
  16. Precutting endoscopic band ligation-assisted resection versus endoscopic submucosal dissection in patients with small gastric submucosal tumors originating from the muscularis propria: study protocol of a randomized controlled trial.2024TrialsFree full text
  17. Does previous gastrectomy history affect the surgical outcomes of laparoscopic cholecystectomy?2023BMC surgeryFree full text
  18. Effectiveness and safety of self-pulling and latter transected reconstruction in totally laparoscopic total gastrectomy: a comparison with laparoscopic-assisted total gastrectomy.2023BMC surgeryFree full text
  19. DNA methylation-related lncRNAs predict prognosis and immunotherapy response in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  20. The Effect of Surgical Approach on Clinical Outcomes in 535 Patients with Remnant Gastric Cancer.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  21. Short-Term and Long-Term Outcomes of Liver Cirrhosis in Gastric Neoplasm Patients Undergoing Endoscopic Submucosal Dissection.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  22. Red blood cell distribution width has a prognostic value for gastric cancer patients after gastrectomy: A pooling-up analysis.2023MedicineFree full text
  23. Comparison of endoscopic submucosal dissection versus surgery for early gastric cancer in the elderly: a pooled analysis.2023World journal of surgical oncologyFree full text
  24. The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis.2023World journal of surgical oncologyFree full text
  25. A nomogram to predict the survival of gastric cancer patients who underwent radical gastrectomy in west China.2022Asian journal of surgery
  26. Does Chronic Kidney Disease Affect the Surgical Outcome and Prognosis of Patients with Gastric Cancer? A Meta-Analysis.2022Nutrition and cancer
  27. Identification and Characterization of the Roles of circCASP9 in Gastric Cancer Based on a circRNA-miRNA-mRNA Regulatory Network.2022Oxidative medicine and cellular longevityFree full text
  28. LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis.2021AgingFree full text
  29. The influence of metabolic syndrome on gastric cancer: A meta-analysis.2021Asian journal of surgery
  30. Successful conversion therapy through gastric transcatheter chemoembolization in advanced gastric cancer: A case report.2021Asian journal of surgery
  31. A simple predictive index for larger estimated blood loss during laparoscopy-assisted total gastrectomy.2021Asian journal of surgery
  32. The outcome of young vs. old gastric cancer patients following gastrectomy: a propensity score matching analysis.2021BMC surgeryFree full text
  33. Novel endoscopic management for small gastric submucosal tumors: A single-center experience (with video).2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  34. Upregulation of ZHX2 predicts poor prognosis and is correlated with immune infiltration in gastric cancer.2021FEBS open bioFree full text
  35. Effect of endoscopic resection on short-term surgical outcomes of subsequent laparoscopic gastrectomy: a meta-analysis.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status10
  1. Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer PatientsStatus unknownNCT06606912Lead sponsorStart 2012-01
  2. SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal MetastasesActive, not recruitingNCT06940921Lead (inferred)Phase 1/Phase 2Start 2025-03
  3. The Effect of Environmental Factors on Gastric Cancer Based on MacrogenomeActive, not recruitingNCT06854146Lead (inferred)Start 2024-11
  4. Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.Active, not recruitingNCT06641700Lead (inferred)Start 2024-10
  5. The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric CancerActive, not recruitingNCT06856382Lead (inferred)Start 2024-12
  6. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  7. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  8. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  9. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  10. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 25 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 7720222023: 4420232024: 6620242025: 332025

23 hospitals in Chongqing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led25
  1. Co-encapsulation of bromelain and doxorubicin in acid-responsive nanogels for enhanced chemotherapy via tumor ECM degradation.2026Journal of biomaterials science. Polymer edition
  2. Integrative single-cell and bulk RNA-seq analysis identifies lactylation-related signature in osteosarcoma.2025Functional & integrative genomics
  3. Hino-Fe Chelate Suppresses Osteosarcoma Progression through Dual Induction of Ferroptosis and NLRC4-mediated Pyroptosis: Mechanisms and Therapeutic Implications.2025International journal of biological sciences
  4. Large Language Model-Assisted Genotoxic Metal-Phenolic Nanoplatform for Osteosarcoma Therapy.2025Small (Weinheim an der Bergstrasse, Germany)
  5. Targeting PERK-ATF4-P21 axis enhances the sensitivity of osteosarcoma HOS cells to Mppα-PDT.2024Aging
  6. Casticin induces ferroptosis in human osteosarcoma cells through Fe2+ overload and ROS production mediated by HMOX1 and LC3-NCOA4.2024Biochemical pharmacology
  7. Advances on immunotherapy for osteosarcoma.2024Molecular cancer
  8. Pyropheophorbide-α methyl ester-mediated photodynamic therapy triggers pyroptosis in osteosarcoma cells via the ROS/caspase-3/GSDME pathway.2024Photodiagnosis and photodynamic therapy
  9. Synergistic induction of ferroptosis by targeting HERC1-NCOA4 axis to enhance the photodynamic sensitivity of osteosarcoma.2024Redox biology
  10. RARRES2 is involved in the "lock-and-key" interactions between osteosarcoma stem cells and tumor-associated macrophages.2024Scientific reports
  11. High Expression of PKMYT1 Predicts Poor Prognosis and Aggravates the Progression of Osteosarcoma via the NF-κB Pathway in MG63 Cells.2023Current cancer drug targets
  12. Genipin Inhibits the Development of Osteosarcoma through PI3K/AKT Signaling Pathway.2023Current pharmaceutical design
  13. DEPDC1 and KIF4A synergistically inhibit the malignant biological behavior of osteosarcoma cells through Hippo signaling pathway.2023Journal of orthopaedic surgery and research
  14. Capsaicin Reduces Cancer Stemness and Inhibits Metastasis by Downregulating SOX2 and EZH2 in Osteosarcoma.2023The American journal of Chinese medicine
  15. A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma.2022Analytical cellular pathology (Amsterdam)
  16. Construction of a Prognosis-Related Gene Signature by Weighted Gene Coexpression Network Analysis in Ewing Sarcoma.2022Computational and mathematical methods in medicine
  17. Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms.2022Journal of nanobiotechnology
  18. Schisandrin B suppresses osteosarcoma lung metastasis in vivo by inhibiting the activation of the Wnt/β‑catenin and PI3K/Akt signaling pathways.2022Oncology reports
  19. Theaflavin-3,3'-Digallate Plays a ROS-Mediated Dual Role in Ferroptosis and Apoptosis via the MAPK Pathway in Human Osteosarcoma Cell Lines and Xenografts.2022Oxidative medicine and cellular longevity
  20. YAP knockdown in combination with ferroptosis induction increases the sensitivity of HOS human osteosarcoma cells to pyropheophorbide-α methyl ester-mediated photodynamic therapy.2022Photodiagnosis and photodynamic therapy
  21. Targeting X box-binding protein-1 (XBP1) enhances the sensitivity of HOS osteosarcoma cells to pyropheophorbide- α methyl ester-mediated photodynamic therapy.2022Photodiagnosis and photodynamic therapy
  22. Targeting GRP78 enhances the sensitivity of HOS osteosarcoma cells to pyropheophorbide-α methyl ester-mediated photodynamic therapy via the Wnt/β-catenin signaling pathway.2021Acta biochimica et biophysica Sinica
  23. Tetrandrine suppresses the growth of human osteosarcoma cells by regulating multiple signaling pathways.2021Bioengineered
  24. The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.2021Journal of orthopaedic surgery and research
  25. Bavachin Induces Ferroptosis through the STAT3/P53/SLC7A11 Axis in Osteosarcoma Cells.2021Oxidative medicine and cellular longevity
Earlier papers (2016–2020)15
  1. MiR-141-3p overexpression suppresses the malignancy of osteosarcoma by targeting FUS to degrade LDHB.2020Bioscience reports
  2. Antitumor effects and mechanisms of pyropheophorbide‑α methyl ester‑mediated photodynamic therapy on the human osteosarcoma cell line MG‑63.2020International journal of molecular medicine
  3. The role of miR-21/RECK in the inhibition of osteosarcoma by curcumin.2020Molecular and cellular probes
  4. MicroRNA-29b sensitizes osteosarcoma cells to doxorubicin by targeting matrix metalloproteinase 9 (MMP-9) in osteosarcoma.2019European review for medical and pharmacological sciences
  5. Honokiol suppresses proliferation and induces apoptosis via regulation of the miR‑21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.2018International journal of molecular medicine
  6. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts.2018Journal of experimental & clinical cancer research : CR
  7. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis.2018Journal of experimental & clinical cancer research : CR
  8. Effect and mechanisms of celastrol on the apoptosis of HOS osteosarcoma cells.2018Oncology reports
  9. Establishment and characterization of human osteosarcoma cells resistant to pyropheophorbide-α methyl ester-mediated photodynamic therapy.2017International journal of oncology
  10. Capsaicin inhibits proliferation and induces apoptosis in osteosarcoma cell lines via the mitogen‑activated protein kinase pathway.2017Oncology reports
  11. Apoptosis and autophagy induced by pyropheophorbide-α methyl ester-mediated photodynamic therapy in human osteosarcoma MG-63 cells.2016Apoptosis : an international journal on programmed cell death
  12. Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways.2016BMC cancer
  13. Mitochondrial pathway and endoplasmic reticulum stress participate in the photosensitizing effectiveness of AE-PDT in MG63 cells.2016Cancer medicine
  14. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.2016International journal of oncology
  15. Aloe-emodin-mediated photodynamic therapy induces autophagy and apoptosis in human osteosarcoma cell line MG‑63 through the ROS/JNK signaling pathway.2016Oncology reports

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 12 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 2.3%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 3320242025: 442025

11 hospitals in Chongqing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06507683

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing

  2. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyGastroenterology / hepatology
Papers it led12
  1. Diagnostic Value of Contrast-Enhanced Ultrasound in Detecting Abdominal Metastases From Gastrointestinal Stromal Tumors.2026Journal of clinical ultrasound : JCU
  2. Development and validation of an ultrasound-based AI-radiomics model for diagnosing and risk-stratifying gastrointestional stromal tumors: a retrospective diagnostic study.2025BMC medical imaging
  3. Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.2025CancerRCT
  4. The role of ultrasound in assessment and prediction of the efficacy of preoperative targeted therapy for gastrointestinal mesenchymal tumors compared with pathology.2025Journal of medical ultrasonics (2001)
  5. Investigation of Nutritional Status by GLIM Criteria in Outpatients with GIST.2025Nutrition and cancer
  6. Advanced gastrointestinal stromal tumor: reliable classification of imatinib plasma trough concentration via machine learning.2024BMC cancer
  7. Preoperative CT-based radiomics and deep learning model for predicting risk stratification of gastric gastrointestinal stromal tumors.2024Medical physics
  8. A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients.2024PloS one
  9. Artificial intelligence-assisted endoscopic ultrasound in the diagnosis of gastrointestinal stromal tumors: a meta-analysis.2023Surgical endoscopy
  10. Escalation of radiotherapy dose in large locally advanced drug-resistant gastrointestinal stromal tumors by multi-shell simultaneous integrated boost intensity-modulated technique: a feasibility study.2022Radiation oncology (London, England)
  11. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.2021Annals of palliative medicine
  12. Novel endoscopic management for small gastric submucosal tumors: A single-center experience (with video).2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Earlier papers (2016–2020)4
  1. Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: A case report.2020Journal of clinical pharmacy and therapeutics
  2. [Whole-course information management in gastrointestinal stromal tumor patients].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.2018Chemotherapy
  4. ShRNA-mediated BMI-1 gene silencing inhibits gastrointestinal stromal tumor cell telomerase activity and enhances apoptosis.2018The Kaohsiung journal of medical sciences
All its trials on ClinicalTrials.gov, any status5
  1. Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GISTRecruitingNCT06507683Lead sponsorN/AStart 2024-05
  2. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  3. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  4. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  5. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

10 hospitals in Chongqing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

5 hospitals in Chongqing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 4 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 222025

4 hospitals in Chongqing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesKidney & bone complications
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 1 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Chongqing for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Chongqing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 8 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.7%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 2220232024: 1120242025: 112025

1 hospital in Chongqing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07699770

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changchun, Chongqing, Kunming, Shenyang, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImagingAntibodies & diagnosisBiologic drugs
Departments in papersRadiology / nuclear medicineNeurology
Papers it led8
  1. Radiomics-based analysis of choroid plexus abnormalities in neuromyelitis optica spectrum disorders and multiple sclerosis and their clinical implications.2025Multiple sclerosis and related disorders
  2. Comparison of diffusion tensor imaging (DTI) tissue characterization parameters in white matter tracts of patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).2024European radiology
  3. Enlarged choroid plexus related to cortical atrophy in multiple sclerosis.2023European radiology
  4. The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab.2023Journal of neuroimmunology
  5. The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder.2022Frontiers in immunologyFree full text
  6. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders.2022Frontiers in immunologyFree full text
  7. Progressive brain microstructural damage in patients with multiple sclerosis but not in patients with neuromyelitis optica spectrum disorder: A cross-sectional and follow-up tract-based spatial statistics study.2021Multiple sclerosis and related disorders
  8. Altered structural networks in neuromyelitis optica spectrum disorder related with cognition impairment and clinical features.2021Multiple sclerosis and related disorders
All its trials on ClinicalTrials.gov, any status2
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory TrialNot yet recruitingNCT07699770Study sitePhase 4Start 2026-06
  2. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08
More papers found outside PubMed (not counted)5
  1. CM-MNet: A Coordinate Space-Aware Mamba-Based Multi-task Model for 3D Fine Lesions in Elongated Structures Segmentation and Diagnosis in MS and NMOSD2025Lecture notes in computer scienceconference-paper
  2. Frequency-domain Decoupled Guided Feature Space Augmentation for Multi-Task Network in Few-Shot Diagnosis of Demyelinating Diseases2025Conference proceedings/Conference proceedings - IEEE International Conference on Systems, Man, and Cyberneticsconference-paper
  3. Point-of-care testing of neuromyelitis optica spectrum disorder using a sonochemically enhanced bifunctional CdTe-ZIF-8 nanohybrids-labelled lateral flow immunoassay2025Chemical Engineering Journalarticle
  4. Ultrasensitive detection of aquaporin-4 antibodies using ZIF-67@PDA@PtCu nanocomposite-based electrochemical immunosensor for neuromyelitis optica spectrum disorder diagnosis2025Journal of Electroanalytical Chemistryarticle
  5. Research progress of gut microbiome in autoimmune diseases of nervous system2022DOAJ (DOAJ: Directory of Open Access Journals)article

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Chongqing for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikes
Papers it led2
  1. Think twice about IgG4-related diseases before operating on hepatic masses.2022Liver international : official journal of the International Association for the Study of the Liver
  2. IgG4-related disease manifesting as scrotal swelling.2021Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 10 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 2.0%.

Papers led
10
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 3320242025: 442025

1 hospital in Chongqing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCrisis & intensive careBiologic & complement drugsAntibodies & diagnosis
Departments in papersNeurology
Papers it led10
  1. Predictors of Quality of Life in Myasthenia Gravis Patients from Southwestern China: Validation of Clinical and Socioenvironmental Determinants.2026Neuroepidemiology
  2. Single-Cell Immune Profiling Reveals Neutrophils Promote Myasthenia Gravis Exacerbation Through BAFF Secretion.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database.2025BMJ openFree full text
  4. Hypothalamic kisspeptin alleviates myasthenia gravis by regulating Th1/Th17/Treg balance through Inhibition of NF-κB signaling pathway.2025Journal of neuroinflammationFree full text
  5. A systematic review of efgartigimod as an effective treatment for myasthenic crisis.2025Naunyn-Schmiedeberg's archives of pharmacology
  6. The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.2024CNS drugs
  7. Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod.2024Frontiers in immunologyFree full text
  8. Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. Single-cell mapping reveals dysregulation of immune cell populations and VISTA+ monocytes in myasthenia gravis.2022Clinical immunology (Orlando, Fla.)
  10. Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report.2022Journal of cardiothoracic surgeryFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia GravisCompletedNCT06707727Lead sponsorStart 2024-07
  2. A Prospective Cohort Study Of Myasthenia GravisStatus unknownNCT04674605Lead sponsorStart 2020-12
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  4. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  5. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  6. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Study sitePhase 3Start 2024-09
  7. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Study sitePhase 2Start 2020-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Chongqing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

6 hospitals in Chongqing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 5 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.6%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 222025

6 hospitals in Chongqing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Chongqing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 28 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 11.4%.

Papers led
28
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 8820212022: 6620222023: 7720232024: 5520242025: 222025

7 hospitals in Chongqing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    AutoInflammatory Disease Alliance Registry (AIDA)
    Phase
    Not given
    Started
    2020-08
    Registry
    NCT05200715

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led28
  1. Proteomic Profiles of Neutrophils from Behcet's Uveitis Patients and their Sex Differences.2025Inflammation
  2. DNA 5-Hydroxymethylcytosine Landscape and Transcriptional Profile Highlight the TUBB4B-Mediated Th17/Th1/Treg Imbalance in Behçet's Uveitis.2025Investigative ophthalmology & visual science
  3. Plasma-derived exosomal protein SHP2 deficiency induces neutrophil hyperactivation in Behcet's uveitis.2024Experimental eye research
  4. 4-Octyl Itaconate Inhibits Proinflammatory Cytokine Production in Behcet's Uveitis and Experimental Autoimmune Uveitis.2024Inflammation
  5. Association of Long Non-coding RNA C1RL-AS1 and PTPN6 Gene Polymorphisms with Ocular Behcet's Disease in Han Chinese.2024Ocular immunology and inflammation
  6. Sensitive optical coherence tomography angiography parameters detecting retinal vascular changes in Behcet's uveitis.2024Photodiagnosis and photodynamic therapy
  7. Combinations of immunomodulatory agents for prevention of uveitis relapse in patients with severe Behçet's disease already on corticosteroid therapy: a randomised, open-label, head-to-head trial.2024The Lancet. RheumatologyRCT
  8. Association of Behçet's disease with the risk of metabolic syndrome and its components: a systematic review and meta-analysis.2023Clinical and experimental medicine
  9. Interferon-α2a induces CD4+ T cell apoptosis and suppresses Th1/Th17 responses via upregulating IRF1-mediated PDL1 expression in dendritic cells from Behcet's uveitis.2023Clinical immunology (Orlando, Fla.)
  10. IL-8 Triggers Neutrophil Extracellular Trap Formation Through an Nicotinamide Adenine Dinucleotide Phosphate Oxidase- and Mitogen-Activated Protein Kinase Pathway-Dependent Mechanism in Uveitis.2023Investigative ophthalmology & visual science
  11. Effects of Plasma-Derived Exosomal miRNA-19b-3p on Treg/T Helper 17 Cell Imbalance in Behçet's Uveitis.2023Investigative ophthalmology & visual science
  12. Gut microbial signatures and their functions in Behcet's uveitis and Vogt-Koyanagi-Harada disease.2023Journal of autoimmunity
  13. Risk factors, clinical features and treatment of Behçet's disease uveitis.2023Progress in retinal and eye research
  14. ANALYSIS OF VASCULAR CHANGES OF FUNDUS IN BEHCET UVEITIS BY WIDEFIELD SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND FUNDUS FLUORESCEIN ANGIOGRAPHY.2023Retina (Philadelphia, Pa.)
  15. Identification of Novel Risk Loci for Behçet's Disease-Related Uveitis in a Chinese Population in a Genome-Wide Association Study.2022Arthritis & rheumatology (Hoboken, N.J.)
  16. The pro-inflammatory effect of triglyceride on human CD4+ T cells and experimental autoimmune uveitis.2022Clinical immunology (Orlando, Fla.)
  17. Transcriptomic profiling of iris tissue highlights LCK signaling and T cell-mediated immunity in Behcet's uveitis.2022Journal of autoimmunity
  18. Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages.2022Neurology(R) neuroimmunology & neuroinflammation
  19. SNP rs7130280 in lncRNA NONHSAT159216.1 confers susceptibility to Behçet's disease uveitis in a Chinese Han population.2022Rheumatology (Oxford, England)
  20. Evaluation of sensitivity and specificity of diagnostic criteria for Behçet's disease in the absence of a gold standard.2022Rheumatology (Oxford, England)
  21. Decreased microRNA-155 in Behcet's disease leads to defective control of autophagy thereby stimulating excessive proinflammatory cytokine production.2021Arthritis research & therapy
  22. Higher 25-hydroxyvitamin D level is associated with increased risk for Behçet's disease.2021Clinical nutrition (Edinburgh, Scotland)
  23. SNP-mediated binding of TBX1 to the enhancer element of IL-10 reduces the risk of Behçet's disease.2021Epigenomics
  24. Metabolomic Analysis of Aqueous Humor Identifies Aberrant Amino Acid and Fatty Acid Metabolism in Vogt-Koyanagi-Harada and Behcet's Disease.2021Frontiers in immunology
  25. Specific sweat metabolite profile in ocular Behcet's disease.2021International immunopharmacology
  26. Tuberculosis Exposure With Risk of Behçet Disease Among Patients With Uveitis.2021JAMA ophthalmology
  27. The Rs12569232 SNP Association with Vogt-Koyanagi-Harada Disease and Behcet's Disease is Probably Mediated by Regulation of Linc00467 Expression.2021Ocular immunology and inflammation
  28. Prevalence and clinical features of systemic diseases in Chinese patients with uveitis.2021The British journal of ophthalmology
Chinese-language papers (not in the count)1
  1. [Literature data mining on the current research status of uveitis in China].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Earlier papers (2016–2020)29
  1. Weak association of a TNFRSF1A polymorphism with Behcet's disease in Chinese Han.2020Experimental eye research
  2. Uveitis genetics.2020Experimental eye research
  3. Aqueous cytokine levels in four common uveitis entities.2020International immunopharmacology
  4. Different Methylation of CpG-SNPs in Behcet's Disease.2019BioMed research international
  5. UVEOGENE: An SNP database for investigations on genetic factors associated with uveitis and their relationship with other systemic autoimmune diseases.2019Human mutation
  6. Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet's Uveitis Not Responding to Conventional Therapy.2019Ocular immunology and inflammation
  7. Epigenome-wide association study identifies Behçet's disease-associated methylation loci in Han Chinese.2019Rheumatology (Oxford, England)
  8. Association of Long Noncoding RNAs Polymorphisms With Ankylosing Spondylitis, Vogt-Koyanagi-Harada Disease, and Behcet's Disease.2018Investigative ophthalmology & visual science
  9. A metagenomic study of the gut microbiome in Behcet's disease.2018Microbiome
  10. Analysis of the association between Fc receptor family gene polymorphisms and ocular Behçet's disease in Han Chinese.2018Scientific reports
  11. Association of LACC1, CEBPB-PTPN1, RIPK2 and ADO-EGR2 with ocular Behcet's disease in a Chinese Han population.2018The British journal of ophthalmology
  12. Decreased expression of A20 is associated with ocular Behcet's disease (BD) but not with Vogt-Koyanagi-Harada (VKH) disease.2018The British journal of ophthalmology
  13. Association of genetic variations in PTPN2 and CD122 with ocular Behcet's disease.2018The British journal of ophthalmology
  14. The Association of Chemokine Gene Polymorphisms with VKH and Behcet's Disease in a Chinese Han Population.2017BioMed research international
  15. Increased Complement 3a Receptor is Associated with Behcet's disease and Vogt-Koyanagi-Harada disease.2017Scientific reports
  16. Genetic polymorphisms of C-type lectin receptors in Behcet's disease in a Chinese Han population.2017Scientific reports
  17. Identification of susceptibility SNPs in IL10 and IL23R-IL12RB2 for Behçet's disease in Han Chinese.2017The Journal of allergy and clinical immunology
  18. Higher Expression of NOD1 and NOD2 is Associated with Vogt-Koyanagi-Harada (VKH) Syndrome But Not Behcet's Disease (BD).2016Current molecular medicine
  19. Association of a NOS3 gene polymorphism with Behçet's disease but not with Vogt-Koyanagi-Harada syndrome in Han Chinese.2016Molecular vision
  20. Genetic Variation in the REL Gene Increases Risk of Behcet's Disease in a Chinese Han Population but That of PRKCQ Does Not.2016PloS one
  21. Association of TNFSF4 Polymorphisms with Vogt-Koyanagi-Harada and Behcet's Disease in Han Chinese.2016Scientific reports
  22. Genetic analysis of innate immunity in Behcet's disease identifies an association with IL-37 and IL-18RAP.2016Scientific reports
  23. Analysis of receptor tyrosine kinase genetics identifies two novel risk loci in GAS6 and PROS1 in Behçet's disease.2016Scientific reports
  24. Genetic polymorphisms of cell adhesion molecules in Behcet's disease in a Chinese Han population.2016Scientific reports
  25. Association between Functional MICA-TM and Behcet's Disease: A Systematic Review and Meta-analysis.2016Scientific reports
  26. Decreased B and T lymphocyte attenuator in Behcet's disease may trigger abnormal Th17 and Th1 immune responses.2016Scientific reports
  27. Genetic Variations of NLR family genes in Behcet's Disease.2016Scientific reports
  28. miR-23a, miR-146a and miR-301a confer predisposition to Vogt-Koyanagi-Harada syndrome but not to Behcet's disease.2016Scientific reports
  29. Two Genetic Variations in the IRF8 region are associated with Behçet's disease in Han Chinese.2016Scientific reports
All its trials on ClinicalTrials.gov, any status1
  1. AutoInflammatory Disease Alliance Registry (AIDA)RecruitingNCT05200715Study siteStart 2020-08

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

14 hospitals in Chongqing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Chongqing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Successful use of tofacitinib in epidermolysis bullosa pruriginosa.2022Clinical and experimental dermatology

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

重庆医科大学附属第一医院

First Affiliated Hospital of Chongqing Medical University

重庆

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
he First Affiliated Hospital of Chongqing Medical University; First affiliated Hospital of Chongqing Medical University; First Affiliated Hospital of Chongqing Medical Universit; First Branch of The First Affiliated Hospital; Affiliated Yongchuan Hospital of Chongqing Medical University; The Affiliated Yongchuan Hospital of Chongqing Medical University; 重庆医科大学附属永川医院

Suggest a correctionDownload the data